From local evidence to global relevance

Fruquintinib was raised as a cautionary example. The China FRESCO study showed a survival benefit and supported Chinese approval in 2018. The international FRESCO-2 study later confirmed benefit in a heavily pretreated global population, enrolling from 2020 to 2021. European approval followed in June 2024. The medicine worked in China and internationally. The issue was not that the original result was false. It was that the original programme did not resolve the questions required for wider use. From Chinese approval to European approval, the translation took about six years. The lesson is not that every China-only programme should include Europe from the beginning. It is that global ambition needs to be visible early enough to influence the pivotal design. The principle should be to identify the real uncertainty and address it, rather than restart an entire development journey because it began elsewhere.

The lesson is not that every China-only programme should include Europe from the beginning.

Inspiring Better Healthcare

Ipsos Rx Insight Store

Contact us

About the Research

Privacy

Cookie Policy